Advances in the treatment of metastatic or unresectable biliary tract cancer

Annals of Oncology

Volumn 21, Issue SUPPL. 7, 2010, Pages

  Valle, J W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; MITOMYCIN C; OXALIPLATIN; PLATINUM DERIVATIVE; VASCULOTROPIN;

BILE DUCT OBSTRUCTION; BILIARY TRACT CANCER; BILIARY TRACT SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; DRUG RESPONSE; DRUG TARGETING; GALLBLADDER CANCER; HUMAN; INOPERABLE CANCER; KARNOFSKY PERFORMANCE STATUS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY OF LIFE; SEPSIS;

EID: 78649385782     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq420     Document Type: Conference Paper

References (22)

1. Vauthey JN, Blumgart LH. Recent advances in the management of cholangiocarcinomas. Semin Liver Dis 1994; 14: 109-114.
2. Khan SA, Taylor-Robinson SD, Toledano MB et al. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol 2002; 37: 806-813.
3. Khan SA, Davidson BR, Goldin R et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut 2002; 51 (Suppl 6): vi1-9.
4. Glimelius B, Hoffman K, Sjoden PO et al. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7: 593-600.
5. Takada T, Nimura Y, Katoh H et al. Prospective randomized trial of 5-fluorouracil, doxorubicin, and mitomycin C for non-resectable pancreatic and biliary carcinoma: multicenter randomized trial. Hepatogastroenterology 1998; 45: 2020-2026.
6. Dwary AD, Sharma A, Mohanti BK et al. A randomized controlled trial (RCT) comparing best supportive care (BSC), 5-FU plus folinic acid (FUFA) and, gemcitabine plus oxaliplatin (GemOx) in management of unresectable gallbladder cancer (GBC). J Clin Oncol 2009; 27(Suppl): Abstr 4521.
7. Rao S, Cunningham D, Hawkins RE et al. Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer. Br J Cancer 2005; 92: 1650-1654.
8. Valle JW, Wasan H, Johnson P et al. Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - the UK ABC-01 study. Br J Cancer 2009; 101: 621-627.
9. Valle J, Wasan H, Palmer DH et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 2010; 362: 1273-1281.
10. Furuse J, Okusaka T, Miyazaki M et al. A randomized study of gemcitabine/cisplatin versus single-agent gemcitabine in patients with biliary cancer. J Clin Oncol 2009; 27 (15 Suppl): Abstr 4579.
11. Eckel F, Schmid RM. Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 2007; 96: 896-902.
12. Andre T, Tournigand C, Rosmorduc O et al. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study. Ann Oncol 2004; 15: 1339-1343.
13. Knox JJ, Hedley D, Oza A et al. Gemcitabine concurrent with continuous infusional 5-fluorouracil in advanced biliary cancers: a review of the Princess Margaret Hospital experience. Ann Oncol 2004; 15: 770-774.
14. Nehls O, Oettle H, Hartmann JT et al. Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer 2008; 98: 309-315.
15. Malka D, Trarbach T, Fartoux L et al. A multicenter, randomized phase II trial of gemcitabine and oxaliplatin (GEMOX) alone or in combination with biweekly cetuximab in the first-line treatment of advanced biliary cancer: interim analysis of the BINGO trial. J Clin Oncol 2009; 27 (15 Suppl): Abstr 4520.
16. Lazaridis KN, Gores GJ. Cholangiocarcinoma. Gastroenterology 2005; 128: 1655-1667.
17. Ogasawara S, Yano H, Higaki K et al. Expression of angiogenic factors, basic fibroblast growth factor and vascular endothelial growth factor, in human biliary tract carcinoma cell lines. Hepatol Res 2001; 20: 97-113.
18. Fava G, Marzioni M, Benedetti A et al. Molecular pathology of biliary tract cancers. Cancer Lett 2007; 250: 155-167.
19. Benckert C, Jonas S, Cramer T et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res 2003; 63: 1083-1092.
20. Tang D, Nagano H, Yamamoto H et al. Angiogenesis in cholangiocellular carcinoma: expression of vascular endothelial growth factor, angiopoietin-1/2, thrombospondin-1 and clinicopathological significance. Oncol Rep 2006; 15: 525-532.
21. Yoshikawa D, Ojima H, Iwasaki M et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer 2008; 98: 418-425.
22. Bekaii-Saab T, Phelps M, Li X et al. A multi-institutional study of AZD6244 (ARRY-142886) in patients with advanced biliary cancers. AACR 2009: Abstr LB 129.